Buccal Cell Cytokeratin 14 Correlates with Multiple Blood Biomarkers of Alzheimer's Disease Risk
Wayne R Leifert, Tori Nguyen, Alan Rembach, Ralph Martins, Stephanie Rainey-Smith, Colin L Masters, David Ames, Christopher C Rowe, S Lance Macaulay, Maxime Francois, Michael F Fenech
Journal of Alzheimer's Disease | IOS PRESS | Published : 2015
We thank Mr. Bryan Yuen (Metasystems Asia) for providing helpful advice on establishing the Metafer software protocol. We thank Jannatul Ferdoush Tuli, Maryam Hor, Theodora Almond, and Candita Dang for assisting with the preparation of microscope slides, and Drs. Sam Burnham, Mary Barnes, and James Doecke for statistical advice. We thank all the participants who took part in this study and the clinicians who referred participants. The Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) study is a collaboration between CSIRO Australia, Edith Cowan University (Perth, Western Australia, Australia), The Florey Institute of Neuroscience and Mental Health (Melbourne, Victoria, Australia), National Ageing Research Institute and Austin Health (Parkville, Victoria, Australia). It also involves support from CogState Ltd. (Melbourne, Victoria, Australia), Hollywood Private Hospital and Sir Charles Gairdner Hospital (Nedlands, Western Australia, Australia). The AIBL study received funding support from the Science and Industry Endowment Fund, National Health and Medical Research Council (NHMRC) and Dementia Collaborative Research Centres (DCRC), Alzheimer's Australia and the McCusker Alzheimer's Research Foundation, as well as Industry, including Pfizer, Merck, Janssen and GE Healthcare. Financial support from the CSIRO's Preventative Health Flagship is gratefully acknowledged. WRL received a grant from The JO&JR Wicking Trust, which is managed by ANZ Trustees (Australia). The authors thank all the AIBL investigators (https://aibl.csiro.au/).